Prosecution Insights
Last updated: October 02, 2026

Examiner: ALFANO, ALAN

Tech Center 1600 • Art Units: 1641 1646

This examiner grants 0% of resolved cases

Performance Statistics

—
Allow Rate
-60.0% vs TC avg
10
Total Applications
—
Interview Lift
0
Avg Prosecution Days
Based on 0 resolved cases, 2023–2026

Rejection Statute Breakdown

2.2%
§101 Eligibility
15.2%
§102 Novelty
19.6%
§103 Obviousness
58.7%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18357665 A CONJUGATE, COMPOSITION AND METHOD FOR NONCOVALENT ANTIBODY CATENATION THAT INCREASES ANTIGEN-BINDING AVIDITY OF AN ANTIBODY IN PROPORTION TO THE DENSITY OF A TARGET ANTIGEN Non-Final OA KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
18353981 CX3CR1-BINDING COMPOUNDS, METHODS AND USES THEREOF Final Rejection Sanofi
17515591 COMPOSITIONS COMPRISING THE PROPEPTIDE OF LYSYL OXIDASE AND USES THEREOF Final Rejection Yeda Research and Development Co. Ltd.
18060296 NEUROPILIN-1 VARIANT ANTIBODIES AND METHODS OF USE Non-Final OA Twist Bioscience Corporation

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month